Physician profile
Jon Stanciu
NPI 1790951705
$4,699.68
in general payments reported to CMS, 2019-2025
24 companies · $602 in 2025
The $602 reported for 2025 was more than what 77% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $370 · 2020: $501 · 2021: $756 · 2022: $846 · 2023: $1,111 · 2024: $514 · 2025: $602.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,211 · Education: $16.11.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,210.86 |
| Education | $16.11 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $1,411.58 | 2019-2025 | Breztri, Airsupra, Farxiga |
| Lilly USA, LLC | $755.19 | 2019-2024 | Mounjaro, Zepbound |
| Amgen INC. | $697.73 | 2021-2023 | Otezla, Repatha |
| Boehringer Ingelheim Pharmaceuticals, INC. | $337.10 | 2019-2025 | Jardiance |
| Biohaven Pharmaceuticals, INC. | $318.71 | 2020-2021 | |
| Exact Sciences Corporation | $269.84 | 2023-2025 | Cologuard Collection Kit |
| Pfizer INC. | $112.42 | 2020-2025 | |
| Novo Nordisk INC | $112.29 | 2024-2025 | Rybelsus, Ozempic |
| Astellas Pharma US INC | $102.21 | 2021-2023 | Myrbetriq |
| Abbvie INC. | $88.94 | 2020-2024 | |
| Amarin Pharma, INC. | $76.23 | 2019-2021 | |
| Kowa Pharmaceuticals America, INC. | $69.76 | 2021-2024 | Zoryve, Livalo, Seglentis |
| Allergan, INC. | $69.16 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $38.14 | 2019-2022 | |
| Antares Pharma, INC. | $37.66 | 2022-2023 | Xyosted, Nocdurna, Tlando |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Idorsia Pharmaceuticals US INC | $37.39 | 2023 | Quviviq |
| Glaxosmithkline, LLC. | $34.12 | 2020-2021 | |
| Horizon Therapeutics Plc | $27.92 | 2019-2020 | |
| Alkermes, INC. | $21.74 | 2025 | Vivitrol |
| Valeritas, INC. | $21.09 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $17.29 | 2025 | Eliquis |
| Nestle Healthcare Nutrition INC. | $16.11 | 2023 | |
| Lupin INC. | $15.97 | 2019 | |
| Redhill Biopharma INC. | $11.09 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jon Stanciu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.